Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca 2+ axis
mBio · 29.06.2023
DOI: 10.1128/mbio.00272-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, online erschienen am 29.06.2023. Verfasst von Su Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Ho…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Benzylisoquinolines, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Researsh and Development Plan, MOST | National Natural Science Foundation of China, guangdong scientific and technological foundation.
Abstract (Originalsprache)
Drug-resistant tuberculosis (TB) poses a major threat to global TB control; consequently, there is an urgent need to develop novel anti-TB drugs or strategies. Host-directed therapy (HDT) is emerging as an effective treatment strategy, especially for drug-resistant TB. This study evaluated the effects of berbamine (BBM), a bisbenzylisoquinoline alkaloid, on mycobacterial growth in macrophages. BBM inhibited intracellular Mycobacterium tuberculosis (Mtb) growth by promoting autophagy and silencing ATG5, partially abolishing the inhibitory effect. In addition, BBM increased intracellular reactive oxygen species (ROS), while the antioxidant N -acetyl-L-cysteine (NAC) abolished BBM-induced autophagy and the ability to inhibit Mtb survival. Furthermore, the increased intracellular Ca 2+ concentration induced by BBM was regulated by ROS, and BAPTA-AM, an intracellular Ca 2+ -chelating agent, could block ROS-mediated autophagy and Mtb clearance. Finally, BBM could inhibit the survival of drug-resistant Mtb. Collectively, these findings provide evidence that BBM, a Food and Drug Administration (FDA)–approved drug, could effectively clear drug-sensitive and -resistant Mtb through regulating ROS/Ca 2+ axis-mediated autophagy and has potential as an HDT candidate for TB therapy. IMPORTANCE It is urgent to develop novel treatment strategies against drug-resistant TB, and HDT provides a promising approach to fight drug-resistant TB by repurposing old drugs. Our studies demonstrate, for the first time, that BBM, an FDA-approved drug, not only potently inhibits intracellular drug-sensitive Mtb growth but also restricts drug-resistant Mtb by promoting macrophage autophagy. Mechanistically, BBM activates macrophage autophagy by regulating the ROS/Ca 2+ axis. In conclusion, BBM could be considered as an HDT candidate and may contribute to improving the outcomes or shortening the treatment course of drug-resistant TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology , Shenzhen, Chin…
- Guangzhou Medical University , Guangzhou, China.
- Department of Clinical Laboratory, The Baoan People's Hospital of Shenzhen, The Second Affiliated Hospital of Shenzhen University , Shenzhen, China.
- Department of Tuberculosis, Guangxi Chest Hospital , Liuzhou, China.
ORCID-Profile: Guoliang Zhang
Förderung
- National Key Researsh and Development Plan
- MOST | National Natural Science Foundation of China
- guangdong scientific and technological foundation
- guangxi scientific and technological foundation
- Shenzhen Scientific and Technological Foundation
Zitieren
APA
Zhang, S., Zhou, X., Ou, M., Fu, X., Lin, Q., Tao, X., Wang, Z., Liu, A., Li, G., Xu, Y., & Zhang, G. (2023). Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca 2+ axis. mBio. https://doi.org/10.1128/mbio.00272-23
Vancouver
Zhang S, Zhou X, Ou M, Fu X, Lin Q, Tao X, et al. Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca 2+ axis. mBio. 2023. doi:10.1128/mbio.00272-23
BibTeX
@article{Zhang2023,
author = {Zhang, Su and Zhou, Xuefeng and Ou, Min and Fu, Xiangdong and Lin, Qiao and Tao, Xiaoyu and Wang, Zhaoqin and Liu, Aimei and Li, Guobao and Xu, Yuzhong and Zhang, Guoliang},
title = {Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca 2+ axis},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.00272-23}
}
EUVIMED